EP2661278

TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY (CDC) ANTIBODIES GENERATED BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS, FOR USE IN THE TREATMENT OF CANCER

  • :
    EP einkaleyfi: Þýðing ekki lögð inn
  • :
    4.1.2012
  • :
    19.6.2019
  • :
    12732263.4
  • :
    3.1.2032
  • :
    TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY (CDC) ANTIBODIES GENERATED BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS, FOR USE IN THE TREATMENT OF CANCER

4.1.2012
19.6.2019
  • :
    SillaJen Biotherapeutics, Inc.
  • :
    450 Sansome Street, Suite 650, 94111, San Francisco, CA, US
  • :
    Sillajen, Inc.
  • :
    307 Hyowon IC Building Pusan National University San 30, 609-735, Busan, KR
  • :
    KIRN, David
  • :
    Mill ValleyCalifornia, US
  • :
    BELL, John
  • :
    OttawaOntario K1H 8L6, CA
  • :
    BREITBACH, Caroline
  • :
    San FranciscoCalifornia, US
  • :
    MOON, Anne
  • :
    San FranciscoCalifornia, US
  • :
    HWANG, Tae-Ho
  • :
    Busan, KR
  • :
    LEE, Yu Kyoung
  • :
    Busan, KR
  • :
    KIM, Mi-kyung
  • :
    Busan, KR
  • :
    201161429622 P
  • :
    4.1.2011
  • :
    US
  • :
    US2012020173
  • :
    4.1.2012
  • :
    A61K 35/768, A61K 35/76, C07K 16/30, A61K 39/395, A61P 35/00, A61K 39/12